Cargando…

Author Correction: A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma

Detalles Bibliográficos
Autores principales:	Wakabayashi, Hiroshi, Inaki, Anri, Yoshimura, Kenichi, Murayama, Toshinori, Imai, Yasuhito, Higuchi, Tetsuya, Jinguji, Megumi, Shiga, Tohru, Kinuya, Seigo
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Nature Publishing Group UK 2022
Materias:	Author Correction
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8770502/ https://www.ncbi.nlm.nih.gov/pubmed/35046473 http://dx.doi.org/10.1038/s41598-022-05239-2

Ejemplares similares

A phase I clinical trial for [(131)I]meta-iodobenzylguanidine therapy in patients with refractory pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

An open-label, single-arm, multi-center, phase II clinical trial of single-dose [(131)I]meta-iodobenzylguanidine therapy for patients with refractory pheochromocytoma and paraganglioma
por: Inaki, Anri, et al.
Publicado: (2021)

Prognostic values of initial responses to low-dose (131)I-MIBG therapy in patients with malignant pheochromocytoma and paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2013)

Biomarker response to high-specific-activity I-131 meta-iodobenzylguanidine in pheochromocytoma/paraganglioma
por: Jimenez, Camilo, et al.
Publicado: (2022)

Feasibility of High-dose Iodine-131-metaiodobenzylguanidine Therapy for High-risk Neuroblastoma Preceding Myeloablative Chemotherapy and Hematopoietic Stem Cell Transplantation: a Study Protocol
por: Araki, Raita, et al.
Publicado: (2018)

Diagnostic Use of Post-therapy (131)I-Meta-Iodobenzylguanidine Scintigraphy in Consolidation Therapy for Children with High-Risk Neuroblastoma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2020)

Utility of (123)I-MIBG Standardized Uptake Value in Patients with Refractory Pheochromocytoma and Paraganglioma
por: Wakabayashi, Hiroshi, et al.
Publicado: (2019)

Thyroid hormone replacement one day before (131)I therapy in patients with well-differentiated thyroid cancer
por: Kayano, Daiki, et al.
Publicado: (2013)

Complete remission of metastatic pheochromocytoma in (123)I-metaiodobenzylguanidine scintigraphy after a single session of (131)I-metaiodobenzylguanidine therapy: a case report
por: Sugino, Teruaki, et al.
Publicado: (2017)

131I-meta-iodobenzylguanidine therapy in neuroblastoma spheroids of different sizes.
por: Gaze, M. N., et al.
Publicado: (1992)

I-131-Metaiodobenzylguanidine therapy with allogeneic cord blood stem cell transplantation for recurrent neuroblastoma
por: Sato, Yuya, et al.
Publicado: (2012)

Application of a tungsten apron for occupational radiation exposure in nursing care of children with neuroblastoma during (131)I-meta-iodo-benzyl-guanidine therapy
por: Taniguchi, Yuka, et al.
Publicado: (2022)

OR03-01 Effects Of Alpha-emitting Meta-(211)At-astato-benzylguanidine ((211)At-MABG) Compared To (131)I-meta-iodobenzylguanidine ((131)I-MIBG) on Tumor Growth Suppression in a Pheochromocytoma Mouse Model
por: Yoshinaga, Keiichiro, et al.
Publicado: (2020)

Efficacy and Safety of High-Specific-Activity (131)I-MIBG Therapy in Patients with Advanced Pheochromocytoma or Paraganglioma
por: Pryma, Daniel A., et al.
Publicado: (2019)

Prediction of accumulation of 131I-labelled meta-iodobenzylguanidine in neuroblastoma cell lines by means of reverse transcription and polymerase chain reaction.
por: Mairs, R. J., et al.
Publicado: (1994)

Correlation between apoptosis and left ventricular remodeling in subacute phase of myocardial ischemia and reperfusion
por: Wakabayashi, Hiroshi, et al.
Publicado: (2015)

Extremity Radioactive Iodine Uptake on Post-therapeutic Whole Body Scan in Patients with Differentiated Thyroid Cancer
por: Wakabayashi, Hiroshi, et al.
Publicado: (2015)

The Vital Role of (131) I-MIBG in Localization of Paraganglioma at Unusual Sites
por: Singhal, Tejasvini, et al.
Publicado: (2022)

I-131 false-positive uptake in a thymic cyst with expression of the sodium-iodide symporter: A case report
por: Yano, Erina, et al.
Publicado: (2022)

Pheochromocytomas and secreting paragangliomas
por: Plouin, Pierre-François, et al.
Publicado: (2006)

Iodine-131 Metaiodobenzylguanidine Therapy for Neuroblastoma: Reports So Far and Future Perspective
por: Kayano, Daiki, et al.
Publicado: (2015)

Low-Dose, Low-Specific Activity (131)I-metaiodobenzyl Guanidine Therapy in Metastatic Pheochromocytoma/Sympathetic Paraganglioma: Single-Center Experience from Western India
por: Barnabas, Rohit, et al.
Publicado: (2021)

Serial examination of cardiac function and perfusion in growing rats using SPECT/CT for small animals
por: Hiromasa, Tomo, et al.
Publicado: (2020)

(123)I-Meta-iodobenzylguanidine Sympathetic Imaging: Standardization and Application to Neurological Diseases
por: Nakajima, Kenichi, et al.
Publicado: (2016)

Diagnosis of Parkinson syndrome and Lewy-body disease using (123)I-ioflupane images and a model with image features based on machine learning
por: Nakajima, Kenichi, et al.
Publicado: (2022)

Multicenter cross-calibration of I-123 metaiodobenzylguanidine heart-to-mediastinum ratios to overcome camera-collimator variations
por: Nakajima, Kenichi, et al.
Publicado: (2014)

[(177)Lu]Lu-DOTA-TATE and [(131)I]MIBG Phenotypic Imaging-Based Therapy in Metastatic/Inoperable Pheochromocytomas and Paragangliomas: Comparative Results in a Single Center
por: Prado-Wohlwend, Stefan, et al.
Publicado: (2022)

Application of (123)I-MIBG myocardial maximum standardized uptake value to characterize cardiac function in patients with pheochromocytoma: comparison with echocardiography
por: Nakajo, Masatoyo, et al.
Publicado: (2022)

Radiosynthesis of no-carrier-added meta-[(124)I]iodobenzylguanidine for PET imaging of metastatic neuroblastoma
por: Green, Michael, et al.
Publicado: (2016)

Pheochromocytoma and paraganglioma: imaging characteristics
por: Baez, Juan C., et al.
Publicado: (2012)

Glycemic Disturbances in Pheochromocytoma and Paraganglioma
por: Ronen, Joshua A, et al.
Publicado: (2019)

Molecular markers of paragangliomas/pheochromocytomas
por: Zhikrivetskaya, Svetlana O, et al.
Publicado: (2017)

Characteristics of Pediatric Pheochromocytoma/paraganglioma
por: Sarathi, Vijaya
Publicado: (2017)

Review of Pediatric Pheochromocytoma and Paraganglioma
por: Bholah, Reshma, et al.
Publicado: (2017)

Preoperative Management of Pheochromocytoma and Paraganglioma
por: Fang, Fang, et al.
Publicado: (2020)

Pheochromocytoma (PHEO) and Paraganglioma (PGL)
por: Pacak, Karel, et al.
Publicado: (2019)

Metastatic Pheochromocytomas and Abdominal Paragangliomas
por: Granberg, Dan, et al.
Publicado: (2021)

Personalized Management of Pheochromocytoma and Paraganglioma
por: Nölting, Svenja, et al.
Publicado: (2021)

Dopamine-Secreting Pheochromocytoma and Paraganglioma
por: Miyamoto, Shotaro, et al.
Publicado: (2021)

Tumour microenvironment in pheochromocytoma and paraganglioma
por: Martinelli, Serena, et al.
Publicado: (2023)

Cannot write session to /tmp/vufind_sessions/sess_u0urld8kr5q0btffkdr35mv77l